InterStim Therapy System, Verify Evaluation System (SNS Bowel Neurostimulator 97800), (SNS Bowel Neurostimulators Impl
Medtronic Neuromodulation · Decision date Oct 29, 2026
What did the FDA decide?
FDA posted a 30-day notice for supplement S354 to PMA P080025, submitted by Medtronic Neuromodulation for the InterStim Therapy System and Verify Evaluation System. The supplement reason is a process change involving the manufacturer, sterilizer, packager, or supplier. The decision field records OK30, and the product code is QON for an implanted electrical device intended for treatment of fecal incontinence.
The statement lists six manufacturing changes: enhanced operator verification of a FactoryWorks processing step and recorded battery pre-weight; addition of pre-weight and post-weight out-of-control action plans to Process Operation Descriptions; software and human machine interface updates that automatically reject batteries above the final-fill reasonable limit; dedicated white work-in-progress trays for electrolyte-filled batteries; an isopropyl alcohol wipe to remove residual electrolyte; and removal of Ball Press and Button Press certification prerequisites from the ram-change procedure, with supervisors and engineers retaining responsibility for operator certification. The notice does not establish safety or clinical effectiveness.
FDA approval order statement
1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 29, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P080025/S354
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Neuromodulation
- Product code
- QON
- Decision code
- OK30
- Decision date
- Oct 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implanted electrical device intended for treatment of fecal incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- QON
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P080025. Subsequent supplements may change the device or its indications.
FDA decision timeline
P080025 · Original PMA
MEDTRONIC INTERSTIM SACRAL NERVE STIMULATION THERAPY SYSTEM
P080025/S352 · Related supplement
InterStim Therapy System, Verify Evaluation System
P080025/S354 received
Application receipt date recorded by FDA.
P080025/S351 · Related supplement
lnterStim Therapy System, Verify Evaluation System
P080025/S353 · Related supplement
InterStim Therapy System, Verify Evaluation System
P080025/S354 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P080025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P080025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA approval | Mar 14, 2011 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 9, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Ms Rcw225, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P080025/S354
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


